Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Conjugated estrogen + fluoxetine is a combination of two pharmacologically active agents used off-label for the management of menopausal depression and climacteric symptoms. Conjugated estrogens are a mixture of naturally occurring estrogens, primarily estrone sulfate and equilin sulfate, used in hormone replacement therapy (HRT) to alleviate symptoms associated with menopause such as hot flashes, vaginal atrophy, and osteoporosis. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases synaptic serotonin levels by inhibiting its reuptake in the central nervous system. The combination leverages both hormonal modulation (via estrogen receptor agonism) and serotonergic neurotransmission enhancement to address mood disturbances and vasomotor symptoms in menopausal women. Clinical studies suggest that this combination may be more effective than HRT alone for treating depressive symptoms during menopause[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on conjugated estrogen + fluoxetine.